Background Although the three vaccines against coronavirus disease 2019 (Covid-19) that
have received emergency use authorization in the United States are highly effective, …

The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
exhibits reduced susceptibility to vaccine-induced neutralizing antibodies, requiring a boost to …

Background: While Coronavirus disease 2019 (Covid-19) vaccines are highly effective,
breakthrough infections are occurring. Booster vaccinations have recently received emergency …

Efforts to develop a range of HIV prevention products that can serve as behaviorally
congruent viable alternatives to consistent condom use and oral pre-exposure prophylaxis (PrEP) …

Worldwide, diabetes is a significant cause of death and disability, accounting for approximately
29 million years of life lost (YLLs) in 2016. Low-and middle-income countries (LMICs) are …

Introduction End‐user perspectives are vital to the design of new biomedical HIV prevention
products. Conjoint analysis can support the integration of end‐user perspectives by …

As part of an ongoing study assessing homologous and heterologous booster vaccines,
following primary EUA series, we assessed neutralization of D614G and Omicron variants prior …

Clinical trials often depend on participants receiving study product to meet objectives of the
protocol. Vitally important are considerations for how sites receive and dispense study …

We gratefully acknowledge the generous support provided by WorkHealth team at
WorkSafe Victoria through the Institute for Safety Compensation and Recovery Research (ISCRR). …

Rapid Decline in Vaccine-Boosted Neutralizing Antibodies Against SARS-CoV-2 Omicron
Variant (preprint) | ssrn; 2022. | PREPRINT-SSRN 主要內容 1 搜索 2 頁腳 3 +A A -A 高對比度 …